linjc16/ctgov huggingface dataset:
Comparison of Methodology Proposed by the SFAR for the Detection by Videoconference of Obstructive Sleep Apnea.

Study Overview
=================
Brief Summary
-----------------
The SFAR (French society of anesthesiology and ICU) proposed a method to detect OSA (Obstructive Sleep Apnea) patients via videoconference. The aim of this study is to compare the result of this method with the results of polysomnography (PSG) which remains the gold standard in the detection of OSA patients.

Detailed Description
-----------------
The SFAR (French society of anesthesiology and ICU) proposed a method to detect OSA (Obstructive Sleep Apnea) patients via videoconference. The aim of this study is to compare the result of this method with the results of polysomnography (PSG) which remains the gold standard in the detection of OSA patients. Other methods, such as a predictive score, also exist. The accuracy of the French method compared to PSG and the predictive scores is to be determined.

Official Title
-----------------
The Aim of This Study is to Determine the Accuracy of the Self-reported Parameters (Compared to Measurement Performed by the Physician) and the Influence of OSA Screening Scores.

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Other: Accuracy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted in the Clinique Saint-Luc of Bouge for a polysomnography Exclusion Criteria: Patient's refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All patients<br>Patients in this group will serve to validate the accuracy of the French method to detect OSA patients in comparison with PSG results. | Other: Accuracy<br>* We will validate the accuracy of the method proposed by the SFAR to detect OSA patients via videoconference (in comparison with the results of the PSG).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of the method proposed by the SFAR by comparison with results of polysomnography. | Validation (or not) of the method proposed by the SFAR to detect OSA patient va videoconference. The SFAR proposed a method to detect OSA patients throughout a videoconference. This method consists in requesting the patient to go around his neck with his two hands. However, this method has not been validated. The outcome of the study is to validate or invalidate the method proposed by the SFAR in comparison with the results of polysomnography (which remains the gold standard for the diagnosis of OSA patients). | 1 month |
A Prognostic Model Based on POCUS at ICU Admission in Critically Ill Patients With Sepsis

Study Overview
=================
Brief Summary
-----------------
Sepsis is responsible for one in three patient deaths. Understanding the severity of the disease, directing medications, prognosticating, and communicating with family members depend on the ability to predict outcomes in a patient presenting with sepsis in the ICU. The outcome of mortality reflects the caliber of ICU treatment. This is a prospective observational study that will include all patients diagnosed with sepsis for point-of-care ultrasonography within 24 hours of admission to the ICU from April 26, 2023, to March 30, 2024, and create a model that will predict 28 day outcome in these patients.

Official Title
-----------------
A Prognostic Model Based on POCUS at ICU Admission in Critically Ill Patients With Sepsis

Conditions
-----------------
Sepsis

Intervention / Treatment
-----------------
* Device: ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >=16 yrs within 24 hour of ICU admission diagnosed as Sepsis as per Sepsis 3 Exclusion Criteria: USG cannot be done within 24 hour of admission to icu If USG cannot be done for 2 parameters Who do not give consent Withdrawal of active life support Do not intubate(DNI) or do not resuscitate(DNR) order at admission

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ultrasound|Patient will undergo multiorgan ultrasonography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28 day status alive or dead | patient will be followed for 28 days from day of icu admission to find out their status being alive or dead | 28 days |
LUTATHERA Injection General Use Result Survey

Study Overview
=================
Brief Summary
-----------------
This study is a multicenter observational study with a central registration system and all-case surveillance system without a control group.

Detailed Description
-----------------
From the date of the first dose of this drug until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart). For patients who discontinue treatment with this drug during the observation period, necessary variables will be examined until 40 weeks after the last dose of this drug during the observation period and recorded in the case report forms (CRF).

Official Title
-----------------
LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)

Conditions
-----------------
Somatostatin Receptor-positive Neuroendocrine Tumor

Intervention / Treatment
-----------------
* Other: LUTATHERA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients treated with this drug for the following indications during a certain post-marketing period Indication: Somatostatin receptor-positive neuroendocrine tumor Patients who started to receive this drug before the contract for this study will also be included in the study population and it will be allowed to register them after the contract so that all patients who receive this drug will be included in this study. Patients treated with this drug for off-label indication will also be included in this study to register all patients received this drug. Exclusion Criteria: Not applicable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| LUTATHERA<br>patients treated with LUTATHERA Injection | Other: LUTATHERA<br>* There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.<br>* Other names: Lutetium oxodotreotide (177Lu);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises | To evaluate the safety about Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises after administration of this drug in a real world setting | Until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart). | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
LUTATHERA
Sexual Function in High-risk Pregnant Women

Study Overview
=================
Brief Summary
-----------------
Our aim with this study is to evaluate the sexual functions of pregnant women whose pregnancies are defined as high-risk pregnancies and whose pregnancies are followed by perinatology specialists.

Official Title
-----------------
Evaluation of Sexual Function in High-risk Pregnant Women

Conditions
-----------------
High Risk Pregnancy, Sexual Dysfunction, Anxiety, Female Sexual Function

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Pregnant women over 18 years old, -Pregnant women 39 years old and under, -Pregnant women in their 3rd trimester. Exclusion Criteria: - Pregnant women under 18 years old, -Pregnant women over 40 years old, -Pregnant women in their 1st or 2nd trimester.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High-risk<br>This group includes pregnant women with the risk factors determined in the study | |
| Normal<br>This group includes pregnant women with no risk | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1 | High-risk pregnant women have lower FSFI score results then normal pregnant women | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
high-risk pregnancy, perinatology, sexual dysfunction, female sexual function, fsfi
Chickpea Pulao Using Fenugreek Seeds and Indian Rennet for Improving Blood Glycaemic Levels

Study Overview
=================
Brief Summary
-----------------
The goal of this study was to perform a clinical trial to compare the impact of herbal chickpea pulao (cooked Indian-Pakistani rice dish) on improving postprandial blood glucose levels in type-2 diabetic people. The main questions it aims to answer are: Whether Indian rennet and fenugreek seed extract can modulate blood sugar levels or not? At what concentration the flavor, taste, and blood sugar impact were acceptable? Participants were provided with control and intervention herbal chickpea pulao for a period of 21 days and asked to provide feedback on taste, flavor, and over-acceptability, and their postprandial blood glucose levels were checked.

Official Title
-----------------
Formulation and Assessment of Chickpea Pulao Using Fenugreek Seeds and Indian Rennet for Improving Blood Glycemic Levels

Conditions
-----------------
Glucose Metabolism Disorders (Including Diabetes Mellitus)

Intervention / Treatment
-----------------
* Dietary Supplement: Fenugreek Seeds and Indian Rennet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People having Type-2 diabetes disease Must be able to consume chickpea rice pulao Must not be on vegan or keto diet Exclusion Criteria: Healthy people without diabetes People with less than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Typical rice pulao without and herbal intervention<br>Normal chickpea rice pulao was used as the main arm. The control group does not contain fenugreek and Indian rennet extract. | |
| Experimental: Chickpea Pulao Using Fenugreek Seeds and Indian Rennet<br>Chickpea rice pulao added with herb (Fenugreek Seeds and Indian Rennet). | Dietary Supplement: Fenugreek Seeds and Indian Rennet<br>* Food herbs like fenugreek Seeds and Indian rennet to formulate rice dish.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in blood glucose levels | Increase or decrease in postprandial glucose levels in mg/dL. | 21 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chickpea pulao, Fenugreek seeds, Indian rennet, Glucose modulating
Expressed Beliefs About the Cause of Pain in a Paediatric Population

Study Overview
=================
Brief Summary
-----------------
The aims of this study are to explore what beliefs children and adolescents manifest about the cause of the pain they describe; to compare whether if there are differences between beliefs by age and by persistence of pain; and to relate explanations of the cause of pain with current scientific evidence to determine if these beliefs are erroneous.

Detailed Description
-----------------
Design: Mixed (explanatory sequential). The primary endpoint of the study were explanations of the cause of pain recorded by means of an open-ended question. Setting: The participants were school-age children attending a charted school in the province of Barcelona. Participants: Of the 345 potential school participants, 306 agreed to participate. 36 pupils were excluded when applying the eligibility criteria, so the resulting sample was of 270.

Official Title
-----------------
Expressed Beliefs About the Cause of Pain in a Paediatric Population: a Mixed Explanatory Sequential Study.

Conditions
-----------------
Chronic Pain, Pediatric ALL, Pain Perception

Intervention / Treatment
-----------------
* Other: Explanations of the cause of pain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: to be schooled at the El Cim school to be between 10 and 16 years old (both included) to have or have had pain in the last month; to be able to read and write in Catalan and/or Spanish. Exclusion Criteria: had an intellectual disability and/or cognitive impairment that interfered with their participation had not submitted the informed consent form duly completed and signed by their legal guardians

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Explanations of the cause of pain|When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'. The themes were sub-classified into sub-themes, according to the type of explanation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Explanations of the cause of pain | Participants were asked to fill out a questionnaire where they were asked Do you have or have you had pain in the last month? and Why do you think you have or have had this pain?. The answer is an open response. | 1 year |
Novamin on Streptococcus Mutans Count in Dental Plaque of High Caries Risk Children

Study Overview
=================
Brief Summary
-----------------
Inhibition of streptococcus mutans can be effective to prevent caries in high caries-risk children. The aim of the study is to evaluate the effect of Novamin on streptococcus mutans in the plaque of high caries-risk children.

Official Title
-----------------
Effect of Toothpaste Containing Novamin on Streptococcous Mutans Count in Dental Plaque of High Caries Risk Children (Randomized Controlled Clinical Trial)

Conditions
-----------------
Dental Plaque, Dental Caries

Intervention / Treatment
-----------------
* Other: Novamin containing toothpaste
* Other: Fluoride containing toothpaste


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medically healthy children. No erupting first permanent molars. High caries risk children; Have visible cavities or have a visible plaque on their teeth. Cooperative (Positive or definitely positive), according to Frankl's Behavior Rating Scale Exclusion Criteria: History of intake of antibiotics for the past 3-4 weeks. History of professional fluoride treatment over 2 weeks before the study. Children with tooth structure defects. Children unable to return for recall visits

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test group<br> | Other: Novamin containing toothpaste<br>* children's teeth will be brushed using Novamin containing toothpaste.<br>|
| Active Comparator: Control group<br> | Other: Fluoride containing toothpaste<br>* children's teeth will be brushed using Fluoride containing toothpaste.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in bacterial count in dental plaque | The samples will be collected from all children in the study and the level of S.mutans will be recorded. | 1 week, 2 weeks and 4 weeks |
Comparison Of Outcome Of Microneedling With Autologous PRP Vs Microneedling With Topical Insulin In Treatment Of Post Acne Atrophic Scars.

Study Overview
=================
Brief Summary
-----------------
Microneedling with topical INSULIN is a simple, effective tool for building body's new collagen layers and thus an alternative to all erosive techniques such as lasers, peels. The skin responds to fine punctures with the release of growth factors. 8 It is a safe procedure that can be performed in the office without complications, with a good cost-benefit because it is economically viable without any effect on patient's daily activities. 9

Official Title
-----------------
Comparison Of The Outcome Of Treatment of Microneedling With Autologous Platelet- Rich -Plasma Versus Microneedling With Topical Insulin In The Treatment Of Post Acne Atrophic Scars.

Conditions
-----------------
ATROPHIC ACNE SCARS

Intervention / Treatment
-----------------
* Drug: PRP( platelet rich plasma) and Insulin human


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: postacne atrophic scars ≥ 2 on Goodman and Baron's acne scar-grading system Either gender. Age 20-50 years. Exclusion Criteria: lactation and pregnancy skin cancers and infection photosensitivity like SLE ,XP use of RETINOIDS in last 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GROUP A Microneedling with PRP(platelete rich plasma)<br> | Drug: PRP( platelet rich plasma) and Insulin human<br>* Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation<br>|
| Experimental: GROUP B Microneedling with topical INSULIN<br> | Drug: PRP( platelet rich plasma) and Insulin human<br>* Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of Topical Insulin R with microneedling versus Platelets rich plasma in atrophic acne scars | Efficacy will be assessed by using Goodman and Baron Qualitative Scar Grading System | Efficacy will be assesed upto 4 months. |
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

Study Overview
=================
Brief Summary
-----------------
The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.

Detailed Description
-----------------
Expanded Access requests are only being considered in response to intermediate size patient population applications. Availability will depend on location.

Official Title
-----------------
An Open-Label, Expanded Access Program of Dupilumab in Adult Patients With Bullous Pemphigoid

Conditions
-----------------
Bullous Pemphigoid

Intervention / Treatment
-----------------
* Drug: dupilumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: 1. Completion of the end of study (EOS) visit in the parent dupilumab phase 2/3 study, R668-BP-1902 (NCT04206553) Key Exclusion Criteria: Patients who, during the parent dupilumab study, R668-BP-1902 (NCT04206553), developed a serious adverse event (SAE) and/or adverse event (AE) deemed related to program drug and which led to discontinuation of investigational product Treatment with non-steroidal immunosuppressive/immunomodulating drug(s) (eg, mycophenolate mofetil, azathioprine, or methotrexate) within 4 weeks before the baseline visit Treatment with BP-directed biologics, as defined in the protocol Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit Planned or anticipated use of any prohibited medications or procedures during program treatment Severe concomitant illness(es) that, in the treating physician's judgment, would adversely affect the patient's participation in the program NOTE: Other protocol defined inclusion/exclusion criteria apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dupilumab|Subcutaneous (SC) administration|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Skin Diseases, Autoimmune Diseases, Immune System Diseases, Inflammatory Diseases